Abstract: Disclosed herein is a method for alleviating osteoarthritis using a composition containing an isolated strain of Lactobacillus delbrueckii subsp. lactis LDL557 which is deposited at Deutsche Sammlung von Mikroorganismen and Zellkulturen GmbH under an accession number DSM 33617.

Abstract: The disclosure provides a method for treating an infection of SARS-CoV-2 infection in a subject, comprising administering to said subject a therapeutically effective amount of a peptide, which is a recombinant fragment human surfactant protein D. The disclosure also provides a pharmaceutical composition for treating an infection of SARS-CoV-2 infection comprising a therapeutically effective amount of the recombinant fragment human surfactant protein D and a pharmaceutically acceptable carrier.

Abstract: Disclosed herein is an isolated strain of Lactobacillus delbrueckii subsp. lactis LDL557, which is deposited at Deutsche Sammlung von Mikroorganismen and Zellkulturen GmbH under an accession number DSM 33617. Also disclosed herein are a composition including the isolated strain of Lactobacillus delbrueckii subsp. lactis LDL557, and use of the isolated strain of Lactobacillus delbrueckii subsp. lactis LDL557 for alleviating an inflammation-related disorder.

Abstract: The present invention provides a lactobacillus strain-containing pharmaceutical composition and food composition for improving of kidney disease and inhibiting inflammation, which comprises an isolated lactic acid bacteria strain. The isolated lactic acid bacteria strain is at least one selected from a group including BLI-02 strain, CGMCC No. 15212, Bifidobacterium longum subsp. infantis, TYCA06 strain, CGMCC No. 15210, Lactobacillus acidophilus, VDD088 strain, CGMCC No. 15211, Bifidobacterium bifidum, and combinations thereof.

Abstract: The present invention provides a lactobacillus strain-containing pharmaceutical composition and food composition for improving of kidney disease and inhibiting inflammation, which comprises an isolated lactic acid bacteria strain. The isolated lactic acid bacteria strain is at least one selected from a group including BLI-02 strain, CGMCC No. 15212, Bifidobacterium longum subsp. infantis, TYCA06 strain, CGMCC No. 15210, Lactobacillus acidophilus, VDD088 strain, CGMCC No. 15211, Bifidobacterium bifidum, and combinations thereof.

Abstract: The preset invention relates to a method for predicting the disease outcome and/or prognosis of chronic obstructive pulmonary disease (COPD) using a variant of surfactant protein D (SP-D) as a biomarker, which is the G-G-C-C-A haplotype of SP-D.

Abstract: The preset invention relates to a method for predicting the disease outcome and/or prognosis of chronic obstructive pulmonary disease (COPD) using a variant of surfactant protein D (SP-D) as a biomarker, which is the G-G-C-C-A haplotype of SP-D.

Abstract: The present invention provides a novel isolated peptide segment which is a Dermatophagoid pteronyssinus (Der p1) antigen epitope, comprising one selected from the group consisting of the peptide segments having the amino acid sequences set forth in SEQ ID NO: 3 and SEQ ID NO: 4, and combination thereof. Also provided is an isolated antibody or antigen binding fragment thereof specific for a Dermatophagoid pteronyssinus (Der p1) antigen, which binds to the peptide segments having the amino acid sequences set forth in SEQ ID NO: 3 and SEQ ID NO: 4, and combination thereof. The present invention further provides a pharmaceutical composition for treating an IgE-mediated disease comprising a therapeutically effective amount of the antibody or antigen binding fragment.

Abstract: The present invention provides a novel isolated peptide segment which is a Dermatophagoid pteronyssinus (Der p1) antigen epitope, comprising one selected from the group consisting of the peptide segments having the amino acid sequences set forth in SEQ ID NO: 3 and SEQ ID NO: 4, and combination thereof. Also provided is an isolated antibody or antigen binding fragment thereof specific for a Dermatophagoid pteronyssinus (Der p1) antigen, which binds to the peptide segments having the amino acid sequences set forth in SEQ ID NO: 3 and SEQ ID NO: 4, and combination thereof. The present invention further provides a pharmaceutical composition for treating an IgE-mediated disease comprising a therapeutically effective amount of the antibody or antigen binding fragment.

Abstract: A method for treating allergy with a pharmaceutical composition containing a detoxified E. coli heat-labile enterotoxin, and, optionally, an allergen.

Abstract: A method for treating allergy with a pharmaceutical composition containing a detoxified E. coli heat-labile enterotoxin, and, optionally, an allergen.

Abstract: Disclosed is a microarray chip for allergy-related immunoglobulin detection, especially for quantitative detection of total IgE and allergen-specific immunoglobulins (such as specific IgE, specific IgG, and specific IgM), which comprises a solid substrate, a reactive layer fabricated on the solid substrate, and at least one allergen or substance capable of binding to immunoglobulin of interest. Whereby, use the result of quantitative detection for allergen-specific IgE to determine hypersensitivity level. In addition, a method for allergy-related immunoglobulin detection using the microarray chip is present, which uses a secondary monoclonal antibody to minimize non-specific binding and applies an enzymatic reaction to amplify reaction signal. An efficient way is thus obtained, which not only reduces time consumption but also provides quantitative measurement.

Abstract: A method of developing a means for detecting a genetic disorder. The method involves identifying a microsatellite marker and a single nucleotide polymorphism marker. Presence of both the microsatellite marker and the single nucleotide polymorphism marker in a subject indicates that the subject is suffering from or at risk for suffering from a genetic disorder.